Dong-A ST, Tobira deal

Dong-A granted Tobira exclusive rights to develop and commercialize evogliptin as a single agent or in combination with Tobira’s cenicriviroc in

Read the full 212 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE